The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA

Nephrology Dialysis Transplantation

Volumn 16, Issue 5, 2001, Pages 1034-1037

  Schmidt, Alice ^a   Gruber, Ursula ^a   Böhmig, Georg ^a   Köller, Elke ^a   Mayer, Gert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

ACE inhibitors; Angiotensin II receptor antagonists; CsA; Renal transplantation; Serum potassium; Serum uric acid

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POTASSIUM; PREDNISOLONE; PROTEIN; URIC ACID;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY TRANSPLANTATION; LABORATORY; MALE; MEAN ARTERIAL PRESSURE; ORTHOSTATIC HYPOTENSION; PARAMETER; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; RECIPIENT; SIDE EFFECT; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

EID: 0035022460     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.5.1034     Document Type: Article

References (21)

1. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 1491-1499
2. Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46: 266-279
3. Cho YW, Teraski Pl, Graver B. Fifteen years graft survival. Clin Transplant 1989; 325-334
4. Barnas U, Schmidt A, Haas M, Oberbauer R, Mayor G. The effects of prolonged angiotensin converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996; 11: 1822-1824
5. Michielsen P, Vanrenterghem Y. Use of NSAIDs in kidney transplantation. Transplant Proc 1993; 25: 2087-2088
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
7. Ruggenenti P, Perna A, Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. J Am Soc. Nephrol 1999; 10: 997-1006
8. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945
9. Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3: 162-169
10. Traindl O, Falger S, Reading S et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55: 1309-1313
11. Borchhardt K, Haas M, Yilmaz N et al. ACE inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52: 1622-1625
12. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox ICH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321: 287-292
13. Kamel KS, Ethier JH, Quaggin S et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who a treated with cyclosporine. J Am Soc Nephrol 1992; 2: 1279-1284
14. Burnier M, Rutschmann B, Nussberger J et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22; 339-347
15. Toto R, Shultz P, Raij L et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertention 1998; 31: 684-691
16. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1999; 66: 268-271
17. Castillo D, Campistol JM, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 54 [Suppl. 68]: S135-139
18. Burnier M, Brunner HR. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nephrol 1996; 4 [Suppl. 1]: 41-46
19. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 [Suppl. 2]: S37-42
20. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333
21. Bakris GL, Siomos M, Bolton WK et al. Differential effects of valsartan and lisinopril on potassium homeostasis in hypertensive patients with nephropathy. J Am Soc Nephrol 1999; 10: 68A.